Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma - Wikidata - awgldk - TriplyDB

Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma

Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma

http://www.wikidata.org/entity/Q36442539

about

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma.Expression of the immune regulation antigen CD70 in osteosarcoma.Immune signature of tumor infiltrating immune cells in renal cancer.Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma.Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.Effects of obesity on immune responses to renal tumors.Overcoming tumor-mediated immunosuppression.Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes Effector CD4 and CD8 T cells and their role in the tumor microenvironment.Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer.CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.Rho GDP dissociation inhibitor-β in renal cell carcinoma.Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.

P2860

Q26801551-F46CF37E-6F9B-47D7-B15B-36ACF6F64D6D Q28393614-F037908E-4409-4D8F-B753-92086D2D1C76 Q33798098-6BAC1747-5451-4429-8EAE-2F31F14C1A47 Q35194116-6D04A7B9-9B74-464F-AB8B-C8DF1D347E5C Q35201895-7AEBE1AF-EB1E-4196-A98E-B96A0AB3A3ED Q35677962-8667C6C8-1ACE-4726-B9F3-1860935D5188 Q35799377-AEF3D7A2-C557-4CCA-8F67-AB93C957FCC9 Q36255816-273813CF-6D07-484E-AC68-0F5463691FB4 Q36643027-6CF14191-D966-4E89-9D6A-A620B4AA4187 Q37320131-46E46AA9-6B24-4931-8F93-40642B3586DF Q37590119-51D3FBCB-0079-4928-B297-4A789CAFEE82 Q38212548-34E6B411-54A5-4508-B4A8-E2EEBD56D4DA Q38262255-8D7AE82C-00E2-46DF-A6B0-66EC2DC46ED4 Q38636573-9366724F-0667-4FC4-97C3-C2E2757D140D Q38726535-6DBA97BF-CD19-4135-8687-BB9BBE4DF292 Q38810926-573307A8-C463-4256-86B5-635710EFD049 Q40321378-024742E4-DAB0-47F7-B2E8-52EECF060F8C Q41880439-692317B5-A4CC-4DD9-ABE6-9EDD8B52F644 Q42952683-E3D5A2E2-7272-46A3-85C1-1738BE67BD75 Q44533312-960313CC-88CA-4201-A163-C470223B9524 Q44549404-DD880311-012B-47FB-A14A-BA9569471729 Q47096248-E4258BA7-BF7E-49F8-B8AD-C4A6BFA1BA34 Q50037939-67E88E30-E209-4120-A3DB-87B03F943EC4

P2860

Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma

http://www.wikidata.org/entity/Q36442539

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Distinctive features of the di ...... lear cell renal cell carcinoma

@ast

Distinctive features of the di ...... lear cell renal cell carcinoma

@en

type

label

Distinctive features of the di ...... lear cell renal cell carcinoma

@ast

Distinctive features of the di ...... lear cell renal cell carcinoma

@en

prefLabel

Distinctive features of the di ...... lear cell renal cell carcinoma

@ast

Distinctive features of the di ...... lear cell renal cell carcinoma

@en

P1433

Q36442539-6287CCC1-6A84-4607-A657-D6C14DD5F3EF

P1476

Q36442539-C77A9BDA-70B9-4FA8-B19D-80EA4D84E006

P2093

Q36442539-064734DB-F391-4C3B-8B87-1C64A37C688E

Q36442539-4E6EF500-0D39-4CEC-B664-A5F91176437E

Q36442539-7F659D9F-5C9F-4187-996A-3A05FD7DA390

Q36442539-A894C55C-58CF-47E0-B837-1D15BEBE8B05

Q36442539-B0C83D31-ADFB-4486-9CC4-4D15690CE5D9

P2860

Q36442539-07E614D4-0448-4263-878C-B69875A0DF08

Q36442539-0FE9084F-5228-4155-AA2B-4C7E225CAB19

Q36442539-1056519F-F7C7-408F-98B5-6CF11C5F7F52

Q36442539-18304A02-70D5-42F6-A21C-3FD653F33458

Q36442539-1C5748BD-2417-42CE-8EB2-F31421A0C4A3

Q36442539-1E20164D-D82A-4C04-9FFD-3BE10FB370A6

Q36442539-3C591A5F-19EF-4933-BFB3-53FE1C178BC7

Q36442539-5738DBAC-E743-45E2-B619-46E441FAE7E5

Q36442539-5763CE70-7EB2-485E-8416-2FF856195BDF

Q36442539-6ACCD68A-5062-409F-A614-4A95DF780710

P304

Q36442539-4BF37713-36C7-4632-BD92-C5203BC05F3E

P31

Q36442539-1A5875B0-43A3-4128-81F3-7F4F03F763BA

P356

Q36442539-2BAAFFD4-4DFC-4E13-BA73-B2B6E17CD536

P407

Q36442539-3544627C-79D2-4958-8852-2AF6045EC6EE

P433

Q36442539-FA7F037B-6288-4706-A393-ECD52A285515

P478

Q36442539-03CBB5F6-08AD-4C5E-8D51-FACFB6425579

P577

Q36442539-FE44D5D1-7D67-496C-BC06-7B5BD4466B58

P5875

Q36442539-B0C30227-A655-41A0-AB15-4BEE6361BEFC

P698

Q36442539-97D6F1D2-2595-43A0-8D7A-112B407660D3

P921

Q36442539-C0BC6116-3E5C-4971-9C3A-AF9DFC577F5A

P932

Q36442539-DE744D1A-81BF-4CD0-BCC6-E7FEE1AA74FF

P356

0008-5472.CAN-12-0588

P1433

Cancer Research

P1476

Distinctive features of the di ...... lear cell renal cell carcinoma

@en

P2093

James C Yang

http://www.w3.org/2001/XMLSchema#string

Ken-Ichi Hanada

http://www.w3.org/2001/XMLSchema#string

Paul F Robbins

http://www.w3.org/2001/XMLSchema#string

Qiong J Wang

http://www.w3.org/2001/XMLSchema#string

Yong F Li

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

CD27 is required for generation and long-term maintenance of T cell immunity.

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.

Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy

P304

6119-6129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-12-0588

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232256701

http://www.w3.org/2001/XMLSchema#string

P698

23071066

http://www.w3.org/2001/XMLSchema#string

P921

P932

3513562

http://www.w3.org/2001/XMLSchema#string